Waldemar Halota

Waldemar Halota

Auto-generated profile, based on publicly available information

Waldemar Halota

Department of Infectious Diseases and Hepatology, Faculty of Medicine, Collegium Medicum Bydgoszcz, Nicolaus Copernicus University, 87-100 Toruń, Poland

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Dorota Zarębska-MichalukDorota Zarębska-Michaluk
Dorota Zarębska-Michaluk
JJJerzy Jaroszewicz
Jerzy Jaroszewicz
APAnna Parfieniuk-Kowerda
Anna Parfieniuk-Kowerda
EJEwa Janczewska
Ewa Janczewska
DDDorota Dybowska
Dorota Dybowska
Robert FlisiakRobert Flisiak
Robert Flisiak
There is still limited data available from real-world experience studies on the pangenotypic regimens in patients with genotype (GT) 3 hepatitis C virus (HCV) infection and liver cirrhosis. The current study aimed to evaluate the efficacy and safety of pangenotypic regimens in this difficult-to-treat population. A total of 236 patients with mean age 52.3 ± 11.3 years and male predominance (72%) selected from EpiTer-2 database were included in the analysis; 72% of them were treatment-naïve. The majority of patients (55%) received the combination of sofosbuvir/velpatasvir (SOF/VEL), 71 without and 58 with ribavirin (RBV), whereas the remaining 107 individuals were assigned to glecaprevir/pibrentasvir (GLE/PIB). The effectiveness of the treatment following GLE/PIB and SOF/VEL regimens (96% and 93%) was higher compared to SOF/VEL + RBV option (79%). The univariate analysis demonstrated the significantly lower sustained virologic response in males, in patients with baseline HCV RNA ≥ 1,000,000 IU/mL, and among those who failed previous DAA-based therapy. The multivariate logistic regression analysis recognized only the male gender and presence of ascites at baseline as the independent factors of non-response to treatment. It should be emphasized that despite the availability of pangenotypic, strong therapeutic options, GT3 infected patients with cirrhosis still remain difficult-to-treat, especially those with hepatic impairment and DAA-experienced.

1 January 2015 in European Journal of Gastroenterology & Hepatology
Verified
Journal Article
Closed access
Robert FlisiakRobert Flisiak
Robert Flisiak
WHWaldemar Halota
Waldemar Halota
KTKrzysztof Tomasiewicz
Krzysztof Tomasiewicz
KKKaja Kostrzewska
Kaja Kostrzewska
HRHomie Razavi
Homie Razavi
EGErin E. Gower
Erin E. Gower
Chronic hepatitis C virus infection is prevalent among 200,000 individuals in Poland; however, few are aware of their condition (30,000 diagnosed) and even fewer are treated (2490 in 2014). This analysis projected future disease burden and developed two treatment scenarios to control or eliminate hepatitis C virus-related disease in Poland.Using a modeling approach, the infected population and future disease progression were quantified. Baseline variables included viremic prevalence, age and sex, diagnosis rate, treatment rate, disease progression, and sustained virologic response rates. Data were collected from the literature and through expert interviews.The number of prevalent hepatitis C virus infections is projected to decrease (5%) by 2030. However, the numbers of individuals with compensated and decompensated cirrhosis, and hepatocellular carcinoma are estimated to increase by 40, 55, and 60%, respectively. By increasing sustained virologic response rates to 95% from 2015 onward, and the number of treated cases (from 2490 to 5000), the number of individuals with cirrhosis, decompensated cirrhosis, and hepatocellular carcinoma is projected to remain constant until 2030. A strategy to eliminate chronic hepatitis C virus infection was also considered. To reduce total infections by 90% and mortality by 80%, treatment was increased to 15,000 patients annually. This scenario required the diagnosis of 15,000 new cases (compared with 3000 today).A marked reduction in hepatitis C virus-related disease burden is possible, with increased diagnosis and treatment. The results could inform the development of effective disease management in Poland.

1 January 2013
Verified
Journal Article
Closed access
APAnatol Panasiuk
Anatol Panasiuk
Robert FlisiakRobert Flisiak
Robert Flisiak
IMIwona Mozer-Lisewska
Iwona Mozer-Lisewska
AAAgnieszka Adamek
Agnieszka Adamek
MTMałgorzata Tyczyno
Małgorzata Tyczyno
ALAnna Lachowicz
Anna Lachowicz

1 September 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Paweł RajewskiPaweł Rajewski
Paweł Rajewski
Dorota Zarębska-MichalukDorota Zarębska-Michaluk
Dorota Zarębska-Michaluk
EJEwa Janczewska
Ewa Janczewska
AGAndrzej Gietka
Andrzej Gietka
WMWłodzimerz Mazur
Włodzimerz Mazur
Robert FlisiakRobert Flisiak
Robert Flisiak
Hepatitis C infection is one of the main reasons for liver cirrhosis and hepatocellular carcinoma. In recent years, more and more is being heard about extrahepatic manifestations of the hepatitis C infection including its possible influence on the development of hypertension and cardiovascular diseases. In the given work, the frequency analysis of the incidence of hypertension and cardiovascular diseases among 2898 HCV-infected patients treated in Poland and the assessment of their relevance to the HCV genotype and the progression of liver fibrosis can be found. The prevalence of hypertension in the group of analyzed patients was 39% and was significantly associated with old age (OR = 1.08 (1.07–1.08)) and female sex, as well as the progression of liver fibrosis (OR = 1.54 (1.29–1.85)). Hypertension was found in 47.6% of patients with F4 fibrosis, 42.1% of patients with F3 fibrosis, and 25% of patients with F1 fibrosis. The incidence of cardiovascular disease in the studied group of patients was as follows: all incidents, 131 (4.52%); including ischemic heart disease 104, (3.95%); stroke, 2 (0.07%); atherosclerosis, 21 (0.72%); and aneurysms, 4 (0.14%). The obtained results prove that the prevalence of cardiovascular diseases is significantly associated with the advanced age of patients and the progression of liver fibrosis. The relevance of sex and the HCV genotype to the prevalence frequency of cardiovascular diseases in the study group has not been proven. This being the case, no differences in the frequency of their incidence depending on the HCV genotype, including genotype 3, was found. Hepatitis C infection as a non-classical risk factor for cardiovascular disease and hypertension does require further studying.

13 January 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Paweł RajewskiPaweł Rajewski
Paweł Rajewski
Dorota Zarębska-MichalukDorota Zarębska-Michaluk
Dorota Zarębska-Michaluk
EJEwa Janczewska
Ewa Janczewska
AGAndrzej Gietka
Andrzej Gietka
WMWłodzimerz Mazur
Włodzimerz Mazur
Robert FlisiakRobert Flisiak
Robert Flisiak
HCV infection is one of the main reasons for liver cirrhosis and hepatocellular carcinoma. In recent years, one finds more and more extrahepatic manifestations of HCV infection, including its possible influence on the development of diabetes. In the presented work, one finds the frequency analysis of the incidence of diabetes among 2898 HCV infected patients treated in Poland, and the assessment of their relevance to the HCV genotype and the progression of fibrosis. The results indicate that the hepatitis C infection seems to be a risk factor for diabetes in persons with more advanced liver fibrosis, for older people, and for the male gender. Thus, one found no differences regarding the frequency of its incidence depending on HCV genotype, including genotype 3.

10 July 2018 in Zakażenia XXI wieku
Verified
Journal Article
Closed access
WHWaldemar Halota
Waldemar Halota
Robert FlisiakRobert Flisiak
Robert Flisiak
JJJacek Juszczyk
Jacek Juszczyk
PMPiotr Małkowski
Piotr Małkowski
MPMałgorzata Pawłowska
Małgorzata Pawłowska
KTKrzysztof Tomasiewicz
Krzysztof Tomasiewicz